文献リスト

1）Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2014. http://www.goldcopd.org/uploads/users/files/GOLD_Report_2014_Jun11.pdf

2）日本呼吸学会COPDガイドライン第4版作成委員会，編．COPD（慢性閉塞性肺疾患）診断と治療のためのガイドライン 第4版．メディカルレビュー社；2013

3）Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008; 359: 1543-54

4）Ichinose M, Fujimoto T, Fukuchi Y. Tiotropium 5 mg via Respimat and 18 mg via HandiHaler; efficacy and safety in Japanese COPD patients. Respir Med. 2010; 104: 228-36

5）Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011; 364: 1093-103

6）Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009; 180: 948-55

7）Bateman E, Tashkin D, Siafakas N, et al. The one-year trial of tiotropium Respimat plus usual therapy in COPD patients. Respir Med. 2010; 104: 1460-72

8）Yohannes AM, Connolly MJ, Hanania NA. Ten years of tiotropium: clinical impact and patient perspectives. Int J Chron Obstruct Pulmon Dis. 2013; 8: 117-25

9）Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008; 300: 1439-50. [Erratum, JAMA 2009;301:1227-30.]

10）Singh S, Loke YK, Enright PL, et al. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ. 2011; 342: d3215

11）Jenkins CR, Beasley R. Tiotropium Respimat increases the risk of mortality. Thorax. 2013; 68: 6-8

12）Wise RA, Anzueto A, Calverley P, et al. The tiotropium safety and performance in RespimatⓇ trial (TIOSPIRⓇ), a large scale, randomized, controlled, parallel-group trial-design and rationale. Respir Res. 2013; 14:40

13）Wise RA, Anzueto A, Cotton D, et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013; 369: 1491-501

14）Jenkins CR. More than just reassurance on tiotropium safety. N Engl J Med. 2013; 369: 1555-6

15）Burgel P, Paillasseur JL, Dusser D, et al. Tiotropium might improve survival in subjects with COPD at high risk of mortality. Respir Res. 2014; 15: 64

16）Sykes DA, Dowling MR, Leighton-Davies J, et al. The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. J Pharmacol Exp Ther. 2012; 343: 520-8

17）D’Urzo A, Ferguson GT, van Noord JA, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res. 2012; 12: 156

18）Kerwin E, Hebert J, Gallagheret N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with moderate-to-severe COPD over 52 weeks: The GLOW2 study. Eur Respir J. 2012; 40: 1106-14

19）Beeh KM, Singh D, Scala LD, et al. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis. 2012; 7: 503-13

20）Sekiya M, Kawayama T, Fukuchi Y, et al. Safety and efficacy of NVA237 once daily in Japanese patients: the GLOW4 trial. [ERS abstract 853970; Session 245; Hall A-7; Date: Mon 3 Sep Time: 12:50-14:40.]

21）Chapman KR, Beeh KM, Beier J, et al. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulmonary Medicine. 2014; 14: 4

22）Vincken W, Aumann J, Chen H, et al. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. Int J Chron Obstruct Pulmon Dis. 2014; 9: 215-28

23）Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J. 2012; 40: 830-6

24）Kerwin EM, D’Urzo AD, Gelb AF, et al. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD. 2012; 9: 90-101

25）Rennard SI, Scanlon PD, Ferguson GT, et al. ACCORD COPD II: A randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clin Drug Investig. 2013; 33: 893-904

26）Karabis A, Lindner L, Mocarski M, et al. Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2013; 8: 405-23

27）Salmon M, Luttmann MA, Foley JJ, et al. Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther. 2013; 345: 260-70

28）Cahn A, Mehta R, Preece A, et al. Safety, tolerability and pharmacokinetics and pharmacodynamics of inhaled once-daily umeclidinium in healthy adults deficient in CYP2D6 activity: a double-blind, randomized clinical trial. Clin Drug Investig. 2013; 33: 653-64

29）hurch A, Beerahee M, Brooks J, et al. Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study. BMC Pulm Med. 2014; 14: 2

30）Trivedi R, Richard N, Mehta R, et al. Umeclidinium in patients with COPD: a randomised, placebo-controlled study. Eur Respir J. 2014; 43: 72-81

31）Balint B, Watz H, Amos C, et al. Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone. Int J Chron Obstruct Pulmon Dis. 2010; 5: 311-8

32）Vogelmeier C, Ramos-Barbon D, Damon J, et al. Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respir Res. 2010; 11: 135

33）Donohue JF, Fogarty C, Lotvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010; 182: 155-62

34）Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010; 65: 473-9

35）Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011; 37: 273-9

36）Decramer ML, Chapman KR, Dahl R, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med. 2013; 1: 524-33

37）Rossi A, Kristufek P, Levine BE, et al. Comparison of the efficacy, tolerability, and safty of formoterol dry powder and oral, slow-release theophylline in treatment of COPD. Chest. 2002; 121: 1058-69

38）van Noord JA, Aumann JL, Janssens E, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest. 2006; 129: 509-17

39）Bogdan MA, Aizawa H, Fukuchi Y, et al. Efficacy and safety of inhaled formoterol 4.5 and 9μg twice daily in Japanese and European COPD patients: Phase III study results. BMC Pulm Med. 2011; 11: 51

40）Hanania NA, Feldman G, Zachgo W, et al. The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD clinical efficacy in COPD of once-daily vilanterol: a randomized placebo-controlled trial. Chest. 2012; 142: 119-27

41）Kempsford R, Norris V, Siederer S. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther. 2013; 26: 256-64

42）Koch A, Pizzichini E, Hamilton A, et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014; 9: 697-714

43）Roskell NS, Anzueto A, Hamilton A, et al. Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol. Int J Chron Obstruct Pulmon Dis. 2014; 9: 813-24

44）Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013; 42: 1484-94

45）Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomized, double-blind, parallel-group study. Lancet Respir Med. 2013; 1: 199-209

46）Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013; 1: 51-60

47）Dahl R, Chapman KR, Rudolf M, et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: The ENLIGHTEN study. Respir Med. 2013; 107: 1558-67

48）ClinicalTrials.gov, n.d. Long term safety and tolerability of QVA149 versus tiotropium in Japanese patients with chronic obstructive pulmonary disease (COPD) (ARISE). [Online] Available at: http://www.clinicaltrials.gov/ct2/show/NCT01285492?term=%28ARISE%29&rank=4

49）Dahl R, Jadayel D, Alagappan VKT, et al. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study. Int J Chron Obstruct Pulmon Dis. 2013; 8: 501-8

50）Beeh KM, Korn S, Beier J, et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir Med. 2014; 108: 584-92

51）Mahler DA, Decramer M, D’Urzo A, et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur Respir J. 2014; 43: 1599-609

52）Kelleher DL, Mehta RS, Jean-Francois BM, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial. PLoS One. 2012; 7: e50716

53）Feldman G, Walker RM, Brooks J, et al. 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: A randomized placebo-controlled trial. Pulm Pharmacol Ther. 2012; 25: 465-71

54）Donohue JF, Maleki-Yazdi MR, Kilbride S, et al. Efficacy and safety of once-daily umeclidinium / vilanterol 62.5/25 mcg in COPD. Respir Med. 2013; 107: 1538-46

55）Cazzola M, Page C, Matera MG. Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulm Pharmacol Ther. 2013; 26: 307-17

56）Scott LJ, Hair P. Umeclidinium/vlanterol: first global approval. Drugs. 2014; 74: 389-95

57）Derom E, Westerman J, Groenke L, et al. The 24-hour lung function profile of once-daily tiotropium and olodaterol fixed-dose combination compared with placebo and monotherapies in chronic obstructive pulmonary disease. 2014 ATS Abstract #A148

58）Jones PW, Singh D, Bateman ED, et al. The effect of aclidinium/formoterol fixed-dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. 2014 ATS Abstract #A3764

59）Vestbo J, Anderson J, Brook RD, et al. The study to understand mortality and morbidity in COPD (SUMMIT) study protocol. Eur Respir J. 2013; 41: 1017-22

60）Dransfield MT, Cockcroft JR, Townsend RR, et al. Effect of fluticasone propionate/salmeterol on arterial stiffness in patients with COPD. Respir Med. 2011; 105: 1322-30

61）Cope S, Donohue JF, Jansen JP, et al. Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis. Respir Res. 2013; 14: 100

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp